公开(公告)号：US20200377578A1

公开(公告)日：2020-12-03

申请号：US16919576

申请日：2020-07-02

Applicant: UCB Biopharma SPRL

Inventor： David Paul Humphreys ,  Daniel John Lightwood ,  Kerry Louise Tyson ,  David Edward Ormonde Knight ,  Karine Jeannine Madeleine Hervé ,  Joanne Elizabeth Compson ,  Matthew Jon Timothy Page ,  Andrew Charles Payne ,  Nicola Louise Fisher ,  Brendon MacKenzie ,  Matthew Cox

IPC: C07K16/12 ,  A61K39/40 ,  A61K45/06 ,  G01N33/569 ,  G01N33/573 ,  G01N33/68

Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.

公开(公告)号：US10766956B2

公开(公告)日：2020-09-08

申请号：US16307444

申请日：2017-06-07

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Bon ,  Joanne Elizabeth Compson ,  Kate Louise Dixon ,  Carl Brendan Doyle ,  Mark Ellis ,  Maria Margarida Gouveia Sancho ,  Raymond Anthony Jupp ,  Lara Kevorkian ,  Daniel John Lightwood ,  Diane Marshall ,  Andrew Charles Payne ,  Joseph Michael David Rastrick ,  Monika-Sarah Schulze ,  Alison Turner ,  Kerry Louise Tyson

IPC: C07K16/22 ,  A61P11/00 ,  A61K9/00 ,  A61P11/12 ,  A61K39/395

Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

公开(公告)号：US20190209567A1

公开(公告)日：2019-07-11

申请号：US16099537

申请日：2017-05-15

Applicant: UCB Biopharma SPRL

Inventor： Rodger Anthony Allen ,  Martin John Armstrong ,  Marina Cavazzana ,  Sven Kracker ,  Duncan Philip McHale ,  Andrew Charles Payne

IPC: A61K31/519 ,  A61P37/06

CPC classification number: A61K31/519 ,  A61P37/06

Abstract: N—{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroethyl}-pyrido[3,2-d]pyrimidin-4-ylamine is effective in the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS).